University of Central Florida

STARS

UCF Patents

Technology Transfer

10-2-2007

Age Determination from Biological Stains Using Messenger RNS Profiling Analysis

John Ballantyne University of Central Florida

Find similar works at: https://stars.library.ucf.edu/patents University of Central Florida Libraries http://library.ucf.edu

This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact STARS@ucf.edu.

Recommended Citation

Ballantyne, John, "Age Determination from Biological Stains Using Messenger RNS Profiling Analysis" (2007). UCF Patents. 16. https://stars.library.ucf.edu/patents/16



US007276340B1

(12) United States Patent

Ballantyne et al.

(10) Patent No.: US 7,276,340 B1 (45) Date of Patent: Oct. 2, 2007

(54) AGE DETERMINATION FROM BIOLOGICAL STAINS USING MESSENGER RNA PROFILING ANALYSIS

- (75) Inventors: John Ballantyne, Orlando, FL (US); Michelle Alvarez, Orlando, FL (US)
- (73) Assignee: University of Central Florida Research Foundation, Inc., Orlando, FL (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 11/232,313
- (22) Filed: Sep. 21, 2005

Related U.S. Application Data

- (60) Provisional application No. 60/612,233, filed on Sep. 22, 2004.
- (51) Int. Cl. *C12Q 1/68* (2006.01)
- (52) U.S. Cl. 435/6; 435/91.1; 435/91.2
- (58) **Field of Classification Search** None See application file for complete search history.

(56) **References Cited**

OTHER PUBLICATIONS

Chomczynski, P. et al., "Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-choloform extraction." (1987), *Analytical Biochemistry*, pp. 162, 156-159.

Juusola, J. and Ballantyne, J., "Messenger RNA profiling: a prototype method to supplant conventional methods for body fluid identification." (2003), *Forensic Science International 135* pp. 85-96.

Livak, J. and Schmittgen, T., "Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta C}_{T}$ Method." (2001), *Methods 25*, pp. 402-408.

Primary Examiner—Teresa E. Strzelecka Assistant Examiner—Heather Calamita (74) Attorney, Agent, or Firm—Brian S. Steinberger; Joyce

P. Morlin; Law Offices of Brian S.Steinberger, P.A.

(57) **ABSTRACT**

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays, systems, methods and kits for the age determination of an individual from bloodstains or samples of unknown origin. The methodology is based on gene expression profiling analysis in which novel human newborn fetal specific genes are identified by detecting the presence of appropriate messenger RNA species.

16 Claims, 14 Drawing Sheets

HBG1

HBG2

HBG1n

Sequence ID 1

HBG2n

Sequence ID 2

Figure 5

Sequence ID 3

cagtctcgcgataactgcg

F 5' gaa-agc-tct-gaa-tca-tcc-agg-tg 3'

Sequence ID 4

6FAM-ttt-gtg-gca-tct-ccc-aag-gaa-gtc-agc MGBNFQ

Sequence ID 5

R 5' agt-caa-ggc-aca-tgg-caa-gaa-g 3'

Sequence ID 6

F 5' gca-gtg-agc-tca-gtg-cag-ttc 3'

Sequence ID 7

6FAM-caa-agg-tgc-cct-tga-gat-cat-cca-gg MGBNFQ

Sequence ID 8

R 5' ttc-ctt-ggg-aga-tgc-cat-aaa 3'

Sequence ID 9

F 5' cca-aag-cga-tct-ctt-ctg-agg-at 3

Sequence ID 10

VIC-cgg-caa-gat-ggc-aga-agt-aga-gca-gaa MGBNFQ

Sequence ID 11

R 5' acg-ccg-cgg-tag-gtg-aa

Sequence ID 12

35

45

50

AGE DETERMINATION FROM **BIOLOGICAL STAINS USING MESSENGER RNA PROFILING ANALYSIS**

This invention claims the benefit of priority from U.S. 5 Provisional Application Ser. No. 60/612,233 filed Sep. 22, 2004 the content of which is incorporated herein by reference.

FIELD OF THE INVENTION

This invention relates to a ribonucleic acid (RNA) based assay system for determining the biological age of an individual from which a body fluid originated.

SEQUENCE LISTING

Appendix A is a sequence listing of mRNA and DNA sequences identified in FIGS. 1-14, the content of Appendix A is also submitted on a compact disc and is incorporated 20 herein by reference. Attached hereto is one compact disc containing the following files:

SEQ. 1 provides the mRNA sequence of HBG1

SEQ. 2 provides the mRNA sequence of HBG2

SEQ. 3 provides the mRNA sequence of HBG1n (Seq. ID 25 1)

SEQ. 4 provides the mRNA sequence of HBG2n (Seq. ID 2)

SEQ. 5 provides the mRNA sequence of S15 (Seq. ID 3) SEQ. 6 provides the DNA sequence of an HBG1n primer 30 (Seq. ID 4)

SEQ. 7 provides the DNA sequences of an HBG1n probe (Seq. ID 5)

SEQ. 8 provides the DNA sequences of an HBG1n primer (Seq. ID 6)

SEQ. 9 provides the DNA sequences of an HBG2n primer (Seq. ID 7)

SEQ. 10 provides the DNA sequences of an HBG2n probe (Seq. ID 8)

SEQ. 11 provides the DNA sequences of an HBG2n 40 primer (Seq. ID 9)

SEQ. 12 provides the DNA sequences of an S15 primer (Seq. ID 10)

SEQ. 13 provides the DNA sequences of an S15 probe (Seq. ID 11)

SEQ. 14 provides the DNA sequences of an S15 primer (Seq. ID 12)

BACKGROUND AND PRIOR ART

It is now a routine matter for forensic scientists to obtain the genetic profile of an individual from deoxyribonucleic acid (DNA) recovered from a biological stain deposited at a crime scene. However, in certain instances where there is no developed suspect as yet or there is no match with any 55 database sample, the DNA profile per se provides no meaningful information to investigators, with the notable exception of gender determination. To aid in these investigations another useful biometric that could provide important probative information is the biological age of an individual. For 60 example, the ability to provide investigators with information as to whether a DNA donor is a newborn baby, an adolescent teenager or an elderly individual could be useful in certain cases, particularly those involving young children such as kidnappings or in providing additional intelligence 65 during terrorist investigations. Currently no reliable validated molecular tests are available for age determination.

2

Numerous molecular theories have been investigated for their correlation with human ageing. Postulated molecular mechanisms include, inter alia, progressive damage to DNA, telomere shortening, long-lived protein glycation and reactive oxygen species (ROS)-mediated oxidative damage to macromolecules. A major downfall to these approaches is that they are characterized by the "degenerative" ageing process, whereby as individuals increase in age the amount of damage also increases, this is especially characteristic of older aged individuals. From the forensic standpoint, however, it would be useful to be able to distinguish between individuals of all age groups and this may require the detection of more subtle molecular changes. An alternate approach to age determination relies on epigenetic and 15 developmental control of gene expression through messenger RNA (mRNA) profiling analysis. This theory of "developmental" ageing, would allow individuals to be categorized into various age groups, each correlated with a specific stage of human development.

The life-cycle of humans comprises a number of developmentally recognized stages. As the human proceeds through these developmental stages, sub-sets of the 20-50 thousand human genes will be differentially expressed. Determining the global gene expression profile (or differential mRNA gene expression profile) present in a biological stain could reveal constellations of genes whose expression is correlated with a specific age. For example, identifying fetal hemoglobin (HBG) and fetal specific regulating mRNA species, isolating pubertal and pre-pubertal hormones and receptors or assaying for DNA damage and repair factors would be indicative of newborn babies, adolescent teenagers and elderly individuals, respectively.

SUMMARY OF THE INVENTION

A primary objective of the present invention is to provide two novel newborn specific fetal hemoglobin genes.

A second objective of the present invention is to provide an mRNA based method for identifying the newborn specific genes present in a bloodstain.

A third objective of the present invention is to provide a kit for the analysis of bloodstains to determine if a particular bloodstain originated from a newborn individual.

A preferred method for identifying whether a stain contains blood of a newborn human being, includes, obtaining a sample stain consisting of a body fluid from a human being, extracting total ribonucleic acid (tRNA) from the sample stain, treating the total RNA with an enzyme, initiating a reverse-transcription (RT) reaction by treating total RNA with random decamer primers and a reverse transcriptase enzyme to produce cDNA, amplifying the cDNA using HBGv-specific and HSK primers with corresponding fluorescently labeled probes, identifying the age of the donor by determining the cycle threshold (Ct) value of a housekeeping gene (HSK) and the Ct value of the HBGv target gene, then subtracting the Ct value of the target gene, from the Ct value of the HSK gene, wherein a positive value would indicate that the blood originates from a newborn human being.

A more preferred method uses the reverse transcriptase enzyme, Moloney Murine Leukemia Virus (MMLV-RT) and has 2 variants of hemoglobin (HBG) used as primers. The 2 variants of HBG are HBG1n and HBG2n and the primers are segments of HBG1n and HBG2n. More preferably, the primers are one or more selected from the sequence ID 4, 5, 6, 7, 8, 9, 10, 11 or 12.

35

65

The preferred identifying probes fluoresce and the values are determined by finding the Ct of the HSK and the Ct of each of the variants of HBG and then subtracting the Ct of the HBGv from the Ct of the HSK, generating a dCt value. The HSK is the ribosomal protein, S15 and the age of the 5 newborn is less than 1 week old or the age of the newborn can be less than 5 months old. More preferably, the HSK is glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

The preferred extracting procedure for the total RNA uses a denaturing solution such as guanidine isothiocyanate- 10 phenol:chloroform. Preferably, the extracted total RNA is precipitated with an organic solvent, such as, isopropanol. The preferred enzyme used to treat the extracted total RNA is deoxyribonuclease I (DNase I).

A preferred gene coding for the human newborn specific 15 fetal hemoglobin variant is HBG1n as in SEQ ID 1 and HBG2n as in SEQ ID 2.

Another preferred gene coding for the human newborn specific fetal hemoglobin variants are HBG1n and HBG2n and polymorphisms thereof.

A preferred kit for use in determining the biological age of an individual in an unknown bloodstain, uses HBG1n and HBG2n and HSK specific primers, preferably, selected from one or more of sequence ID 4, 5, 6, 7, 8, 9, 10, 11, or 12; the preferred housekeeping gene is the ribosomal protein, S15. 25 The preferred probes are labeled with fluorescent dyes.

Further objects and advantages of this invention will be apparent from the following detailed description and example of a presently preferred embodiment.

BRIEF DESCRIPTION OF THE FIGURES

- FIG. 1 provides the mRNA sequence of HBG1
- FIG. 2 provides the mRNA sequence of HBG2
- FIG. 3 provides the mRNA sequence of HBG1n
- FIG. 4 provides the mRNA sequence of HBG2n
- FIG. 5 provides the mRNA sequence of S15
- FIG. 6 provides the DNA sequence of an HBG1n primer
- FIG. 7 provides the DNA sequences of an HBG1 n probe
- FIG. 8 provides the DNA sequences of an HBG1n primer 40
- FIG. 9 provides the DNA sequences of an HBG2n primer
- FIG. 10 provides the DNA sequences of an HBG2n probe
- FIG. 11 provides the DNA sequences of an HBG2n primer
- FIG. 12 provides the DNA sequences of an S15 primer
- FIG. 13 provides the DNA sequences of an S15 probe FIG. 14 provides the DNA sequences of an S15 primer

DESCRIPTION OF THE PREFERRED **EMBODIMENTS**

Before explaining the disclosed embodiments of the present invention in detail it is to be understood that the invention is not limited in its application to the details of the particular arrangements shown since the invention is capable of other embodiments. Also, the terminology used herein is 55 for the purpose of description and not of limitation.

Below is a listing of several acronyms used herein: DNA is deoxyribonucleic acid

- Ct is cycle threshold value; it is the cycle number at which the fluorescent signal passes a pre-determined threshold. 60
- HBG is hemoglobin
- HSK is housekeeping gene
- RNA is ribonucleic acid
- mRNA is messenger ribonucleic acid
- ROS is reactive oxygen species
- RT-PCR is reverse transcription polymerase chain reaction S15 is ribosomal protein

4

The life-cycle of humans comprises a number of developmentally recognized stages. As the human proceeds through these developmental stages, sub-sets of the 20-50 thousand human genes will be differentially expressed. Determining the global gene expression profile (or differential mRNA gene expression profile) present in a biological stain could reveal constellations of genes whose expression is correlated with a specific age. For example, identifying fetal hemoglobin and fetal specific regulating mRNA species, isolating pubertal and pre-pubetal hormones and receptors or assaying for DNA damage and repair factors, would be indicative of newborn babies, adolescent teenagers and elderly individuals, respectively.

A clear example of age related differential gene expression involves the fetal to adult hemoglobin shift. The human beta-hemoglobin locus is located on the short arm of chromosome 11 (11p15.5), and encodes five functional beta-like globin genes: epsilon, gammaG, gammaA, delta, and beta, (hemoglobin gamma mRNA sequences, HBG1 (gammaA) and HBG2 (gammaG), are provided in FIG. 1 and FIG. 2, respectively).

The expression of embryonic hemoglobin (epsilon) commences in the yolk sac in the early stages of gestational development. During the fifth week of gestation the fetal liver, spleen and bone marrow begin to express the fetal specific gamma hemoglobin chains (gammaA and gammaG) to form the fetal hemoglobin protein. This up-regulation of gamma-globin is accompanied by a shutdown of epsilonglobin synthesis. Shortly before birth, beta-globin gene 30 expression commences in the bone marrow, forming adult hemoglobin and inturn gamma-globin expression is down regulated. Therefore, the development of an assay which identifies gamma hemoglobin mRNA in a biological stain, would indicate that the donor of the stain is a newborn baby.

The gamma hemoglobin locus was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) using two sets of highly specific primers, one designed to specifically amplify HBG1 (gammaA) and one designed for amplification of HBG2 (gammaG). In contrast to our initial hypothesis, a messenger RNA (mRNA) product corresponding to the individual HBG1 or HBG2 genes was amplified in all age groups tested. These results demonstrated that the production of gamma hemoglobin mRNA is not restricted to the fetal and newborn stages of development. Upon further investigation of these RT-PCR assays, the presence of an 45 additional lower molecular weight amplimer was detected in only newborn individuals. These lower molecular weight products were excised, cloned, sequenced and aligned with the standard hemoglobin genes. Alignment analysis revealed these lower molecular weight amplimers to be variants of the standard gamma hemoglobin genes (HBGv) which we have termed HBG1n and HBG2n (variant gamma hemoglobin mRNA sequences HBG1n and HBG2n are provided in FIG. 3 and FIG. 4, respectively).

Based on this process the invention provides real-time PCR duplexes which are composed of one novel newborn specific fetal hemoglobin variant, HBG1n or HBG2n, whose sequences are identified as SEQUENCE ID 1 (HBG1n) (FIG. 3), SEQUENCE ID 2 (HBG2n) (FIG. 4), and one housekeeping gene (HSK), which may be the ribosomal protein, S15, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or others (example of a HSK gene sequence, S15, (SEQUENCE ID 3) (FIG. 5)). The collection of genes that are expressed within the constellation of differentiated cells that make up a body fluid is called the multicellular transcriptome. These genes comprise ubiquitously expressed housekeeping (HSK) genes, which are responsible for cell

maintenance functions independent of biological age, and genes that are specifically expressed in an age dependent manner.

Fluorescent (i.e. FAM (6-carboxyfluorescein) and VIC) dye-labeled probes (i.e. minor groove binding non-fluorescent quencher (MGBNFQ)) and their corresponding unlabeled primers are incorporated into the real-time PCR (qPCR) reaction. These qPCR duplexes have been optimized to determine if a bloodstain originated from a newborn individual and are sensitive with as little as 50 pg of 10 input RNA (into the qPCR reaction). The real-time qPCR methodology is based on determining the delta cycle threshold (dCt) values generated using the cycle threshold (Ct) of the HSK gene and the Ct of the novel hemoglobin variants (HBGv) (dCt=Ct S15-Ct HBGv). A positive dCt value 15 would indicate a newborn origin; in contrast a negative dCt value would be obtained with all other ages.

An mRNA based approach for age determination, such as the real time PCR assays described above, could allow the facile identification of the newborn specific genes present in ²⁰ a bloodstain and could rapidly become a validated molecular test for newborn specific age determination.

As an example, the assay of the invention can be performed in two fashions: one in which the newborn is identified as less than 1 week old; the other as less than 5 ²⁵ months old, depending on the amount of material used.

The following example provides further explanation of the present invention.

EXAMPLE 1

For RNA isolation, total RNA is extracted from a bloodstain using a denaturing solution, composed of guanidine isothiocyanate, the RNA is isolated with acid phenol:chloroform and precipitated with isopropanol and GlycoBlueTM ³⁵ glycogen carrier (from Ambion Inc., Austin, Tex.). The RNA is centrifuged and the pellet is washed once with a 75% ethanol/25% DEPC-treated water solution. The pellet is dried, re-solubilized and stored in an RNAsecure Resuspension Solution (Ambion Inc., Austin, Tex.). Next, the 40 extracted total RNA is treated with an enzyme, deoxyribonuclease I (TURBO[™] DNase (RNase-Free)) (Ambion Inc., Austin, Tex.), quantitated using the unsymmetrical cyanine dye RiboGreen® (Molecular Probes, Eugene, Oreg.) and then reverse-transcribed using fifty micromolar random 45 decamers as the first strand primer, producing complementary DNA (cDNA). The Moloney Murine Leukemia Virus-Reverse Transcriptase enzyme (MMLV-RT) from Ambion Inc., Austin, Tex., was used in this case. Finally, the cDNA is amplified using housekeeping and newborn gene-specific $_{50}$ primers (as exemplified in FIGS. 6-14).

Based on the above extraction and purification technique, duplex real-time PCR assays using in this case the Taqman® Universal PCR Master Mix in the 7000 Sequence detection System from Applied Biosystems, Foster City, Calif., and standard cycling conditions such as: Step 1: 1 cycle of 50 degrees C., for 2:00 minutes; Step 2: 1 cycle of 95 degrees C., for 10:00 minutes; Step 3: 40-50 cycles of 95 degrees C., for 0:15 seconds and 60 degrees C., for 1:00 minute; wherein data is collected at stage 3, step 2 (60 degrees C., for 1:00) were developed which can definitively identify newborn RNA. These duplex reactions are composed of one of the two novel variant forms of newborn gamma hemoglobin (HBGv), HBG1n or HBG2n, and a housekeeping (HSK) gene, the ribosomal protein, S15 and have been optimized for the detection of newborn individuals from bloodstains. 65 The methodology is based on gene expression profiling analysis in which the HBGv genes are identified by detect-

ing the presence of appropriate mRNA species. The genespecific primers are incorporated with fluorescently labeled probes (i.e. FAM and VIC) into a single multiplexed quantitative polymerase chain reaction (qPCR). The mRNA is amplified and this amplification is detected by determining the fluorescent emission of the dye-labeled probe.

EXAMPLE 2

In an assay of the invention which identifies newborns that are from 1 hour to 1 week in biological age one may proceed as Example 1 above using:

HBG1n

50 nanomolar of each primer (Forward and Reverse) 250 nanomolar of the probe

HBG2n

50 nanomolar of each primer (Forward and Reverse) 250 nanomolar of the probe

S15

900 nanomolar of each primer (Forward and Reverse) 250 nanomolar of the probe

EXAMPLE 3

In an assay of the invention which identifies newborns that are from 1 hour to 5 months in biological age one may proceed as in Example I above using:

HBG1n

100 nanomolar of each primer (Forward and Reverse) 250 nanomolar of the probe

HBG2n

50 nanomolar of each primer (Forward and Reverse) 250 nanomolar of the probe

S15

600 nanomolar of each primer (Forward and Reverse) 250 nanomolar of the probe

EXAMPLE 4

The cycle threshold (Ct) values obtained are used to determine the delta Ct (dCt) for that particular sample. The ₅₅ equation for dCt calculation is:

Ct(S15)-Ct(HBG1n)=dCt

Ct(S15)-Ct(HBG2n)=dCt

60 If the dCt value is positive then the sample originated from a newborn.

If the dCt value is negative then the sample originated from an age other than newborn.

If no Ct value is generated with the newborn genes (HBG1n or HBG2n) the sample is given a Ct value of 40.000 (the maximum number of cycles), for that particular gene. If no

Ct value is generated with the housekeeping gene (S15) than the assay must be repeated.

While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or modifications which it has presumed in practice, the scope 8

of the invention is not intended to be, nor should it be deemed to be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth and scope of the claims here appended.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 14 <210> SEQ ID NO 1 <211> LENGTH: 584 <212> TYPE: DNA <213> ORGANISM: HBG1 <400> SEQUENCE: 1 acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 ttgacagett tggcaacetg teetetgeet etgecateat gggcaaceee aaagteaagg 240 cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgatctca 300 agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga 360 acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat 420 tcacccctga ggtgcaggct tcctggcaga agatggtgac tgcagtggcc agtgccctgt 480 cctccagata ccactgagct cactgcccat gattcagagc tttcaaggat aggctttatt 540 ctgcaagcaa tacaaataat aaatctattc tgctgagaga tcac 584 <210> SEQ ID NO 2 <211> LENGTH: 583 <212> TYPE: DNA <213> ORGANISM: HGB2 <400> SEQUENCE: 2 acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca 300 agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga 360 acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat 420 tcacccctga ggtgcaggct tcctggcaga agatggtgac tggagtggcc agtgccctgt 480 cctccagata ccactgagct cactgcccat gatgcagagc tttcaaggat aggctttatt 540 ctgcaagcaa tcaaataata aatctattct gctaagagat cac 583 <210> SEQ ID NO 3 <211> LENGTH: 367 <212> TYPE: DNA <213> ORGANISM: HBG1n <400> SEQUENCE: 3 acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 120 atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180

27

9

-continued

ttgacagctt	tggcaacctg	tcctctgcct	ctgccatcat	gggcaacccc	aaagtcaagg	240	
cacatggcaa	gaaggtgctg	acttccttgg	gagatgccac	aaagcacctg	gatgattcag	300	
agctttcaag	gataggcttt	attctgcaag	caatacaaat	aataaatcta	ttctgctgag	360	
agatcac						367	
<210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN	D NO 4 H: 421 DNA IISM: HBG2n						
<400> SEQUE	NCE: 4						
acactcgctt	ctggaacgtc	tgaggttatc	aataagctcc	tagtccagac	gccatgggtc	60	
atttcacaga	ggaggacaag	gctactatca	caagcctgtg	gggcaaggtg	aatgtggaag	120	
atgctggagg	agaaaccctg	ggaaggctcc	tggttgtcta	cccatggacc	cagaggttct	180	
ttgacagctt	tggcaacctg	tcctctgcct	ctgccatcat	gggcaacccc	aaagtcaagg	240	
cacatggcaa	gaaggtgctg	acttccttgg	gagatgccat	aaagcacctg	gatgatctca	300	
agggcacctt	tgcccagctg	agtgaactgc	actgagctca	ctgcccatga	tgcagagctt	360	
tcaaggatag	gctttattct	gcaagcaatc	aaataataaa	tctattctgc	taagagatca	420	
c						421	
<210> SEQ ID NO 5 <211> LENGTH: 531 <212> TYPE: DNA <213> ORGANISM: S15							
<400> SEQUE	NCE: 5						
ggcagtctcg	cgataactgc	gcaggcgcgg	accaaagcga	tctcttctga	ggatccggca	60	
agatggcaga	agtagagcag	aagaagaagc	ggaccttccg	caagttcacc	taccgcggcg	120	
tggacctcga	ccagctgctg	gacatgtcct	acgagcagct	gatgcagctg	tacagtgcgc	180	
gccagcggcg	gcggctgaac	cggggcctgc	ggcggaagca	gcactccctg	ctgaagcgcc	240	
tgcgcaaggc	caagaaggag	gcgccgccca	tggagaagcc	ggaagtggtg	aagacgcacc	300	
tgcgggacat	gatcatccta	cccgagatgg	tgggcagcat	ggtgggcgtc	tacaacggca	360	
agaccttcaa	ccaggtggag	atcaagcccg	agatgatcgg	ccactacctg	ggcgagttct	420	
ccatcaccta	caagcccgta	aagcatggcc	ggcccggcat	cggggccacc	cactcctccc	480	
gcttcatccc	tctcaagtaa	tggctcagct	aataaaggcg	cacatgactc	С	531	
<210> SEQ ID NO 6 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: HEGIn							
<400> SEQUE	NCE: 6						
gaaagctctg	aatcatccag	gtg				23	
<210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN	D NO 7 H: 27 DNA HISM: HBG1n						
<400> SEQUE	NCE: 7						

tttgtggcat ctcccaagga agtcagc

<pre>clos SEC ID NO 8 clos SECUENCE: 8 agtcaagtca catggcaaga ag clos SECUENCE: 8 clos SECUENCE: 8 agtcaagtca catggcaaga ag clos SECUENCE: 9 gcacgtagtagt catgcaagta ag clos SECUENCE: 9 clos SECUENCE: 9 clos SECUENCE: 9 clos SECUENCE: 10 clos SECUENCE: 10 clos SECUENCE: 11 clos SECUENCE: 11 clos SECUENCE: 11 clos SECUENCE: 12 clos SECUENCE: 13 clos SECUENCE: 13 clos SECUENCE: 14 clos SECUENCE: 14 clos SECUENCE: 14 agccagggt agstgaa 17</pre>		-continued	
<pre>-210 - 550 U NO 8 -210 - 550 U NO 8 -210 - 550 U NO 8 -210 - 550 U NO 10 -210 - 550 U NO 11 -210 - 550 U NO 11 -210 - 550 U NO 11 -210 - 550 U NO 12 -210 - 550 U NO 14 -211 - L550 U H -210 - 12 -210 -210 -210 -21 -210 -210 -210 -210 -210 -21 -210 -210 -210 -21 -210 -21</pre>			
2112 TUPE IN HEBGIN 212 CUPE IN HEBGIN 213 CORDATION HEBGIN 40000 SEQUENCE: 8 40000 SEQUENCE: 9 9024126 TUPE INNA 4130 CREATION: 9 9034130 SEQUENCE: 9 9034141 CREATION: 9 9034152 CREATION: 9 90341541000000000000000000000000000000000	<210> SEQ ID NO 8		
213 - ORGANIESK HEGIN -400 - ESQUENCE: 8 agtoaaggoa catggoaaga ag 22 -10 - SEQUENCE: 8 agtoaaggoa catggoaaga ag 22 -10 - SEQUENCE: 9 21 gaagtagagt cagtgoagt c 21 -210 - SEQUENCE: 9 21 gaagtagagt cagtgoagt c 21 -210 - SEQ UENCE: 9 21 gaagtagagt cagtgoagt c 21 -210 - SEQ UENCE: 9 26 -210 - SEQ UENCE: 10 26 caaaggtgoc cttgagata tocagg 26 -210 - SEQ UENCE: 10 26 cals - Sequence: 10 21 caaaggtgoc cttgagata tocagg 26 -210 - SEQ UENCE: 11 21 ttocttggga gatgocata a 21 -210 - SEQ UENCE: 11 21 ttocttggga gatgocata a 21 -210 - SEQUENCE: 12 21 -210 - SEQUENCE: 13 23 -210 - SEQUENCE: 14 23 -210 - SEQUENCE: 13 21 -210 - SEQUE	<211> LENGTH: 22		
24.00 > EQUENCE: 8 agtcaaggcc catggcagg ag 22 c100 > EQUENCE: 8 agtcaaggcc catggcagg ag 21 c110 > EQUENCE: 9 21 c210 > EQUENCE: 10 21 casaggtgcc catggagta agtoggagta 26 c210 > EQUENCE: 10 26 casaggtgcc catggagta agtoggagta 26 c210 > EQUENCE: 10 20 casaggtgcc catggagta agtoggagta 21 c210 > EQUENCE: 10 20 casaggtgcc catggagta agtoggagta 21 c210 > EQUENCE: 11 20 tccttgg gatgccatas a 21 c210 > EQUENCE: 11 21 tccttgg gatgccatas a 21 c210 > EQUENCE: 12 23 coasaggagt cctctctgg gat 23 c210 > EQUENCE: 13 21 casgcugagtg gcagagtag agcogaa 27 c210 > EQUENCE: 13 21 casgcugagtg gcagagtag agcogaa 27 c210 > EQUENCE: 13 21 casgcugunce: 14 210 <	<212> TYPE: DNA		
<pre>4400 SEQUENCE: 8 agtcaaggca catggcaaga ag 22 410 SEQUENCE: 9 gcagtgagct cagtgcagtt c 210 SEQUENCE: 9 gcagtgagct cagtgcagtt c 210 SEQUENCE: 9 gcagtgagct cagtgcagtt c 210 SEQUENCE: 10 caaaaggtgcc ctgagatca tocagg 26 4100 SEQUENCE: 10 caaaaggtgcc ctgagatca tocagg 26 410 SEQUENCE: 11 ttocttggga gatgccataa a 21 410 SEQUENCE: 11 ttocttggga gatgccataa a 21 410 SEQUENCE: 12 ccaaaaggtg cttottutgag gat 21 410 SEQUENCE: 13 cgcaaagtag cagtagata agcagaa 21 410 SEQUENCE: 13 cgcaaagtag gcagaagtag agcagaa 21 410 SEQUENCE: 13 cgcaaagtag gcagaagtag agcagaa 21 410 SEQUENCE: 13 cgcaaagtag gcagaagtag agcagaa 21 410 SEQUENCE: 13 cgcaagtag gcagaagtag agcagaa 21 410 SEQUENCE: 13 cgcaagtag gcagaagtag agcagaa 21 410 SEQUENCE: 13 cgcaagtagt gcagaagtag agcagaa 21 410 SEQUENCE: 13 cgcaagtagt gcagaagtag agcagaa 21 410 SEQUENCE: 13 cgcaagtagt gcagaagtag agcagaa 21 410 SEQUENCE: 14 agccacggtgt agtgca 17 410 SEQUENCE: 14 3 410 SEQUENCE: 14</pre>	(215) OKGANISM. IIDGIII		
agtcaaggca catgigcaaga ag 22 <210> SEQ ID NO 9	<400> SEQUENCE: 8		
<pre>c11> SEQ ID NO 9 c11> LENOTH: 21 c21> TYPE: NM c11> SEQUENCE: 9 gragtgagt cagtgagt c c 21 c10> SEQUENCE: 9 gragtgagt cagtgagt c c 21 c10> SEQUENCE: 10 caaaggtgc cutaggatca tocagg c10> SEQUENCE: 11 ttocutagga gatgocataa a c11> cutaggat cutout gat cutaggat cutagga</pre>	agtcaaggca catggcaaga ag		22
-210- SEND TO NO 9 -211- LENDER: 21 -212- CONSIN: HEG2D. -213- ORGANISM: HEG2D. -214- SOUCHACE: 9 geagtgagt cagtgeagtt c -210- SEQ LD NO 10 -211- LENDER: 76 -212- SEQUENCE: 10 caaaggtgoc cttgagatoa toccagg -210- SEQ LD NO 11 -211- LENDER: 21 -210- SEQ LD NO 11 -211- LENDER: 21 -210- SEQ UENCE: 10 caaaggtgoc cttgagatoa toccagg -210- SEQ UENCE: 11 ttocttggg gagtgocataa a -210- SEQ UENCE: 11 ttocttggg gatgocataa a -210- SEQ UENCE: 12 coaaaggtgat ctctctcgg gat -210- SEQ UENCE: 12 coaaaggtgat ctctctcgg gata -210- SEQ UENCE: 13 cito SEQUENCE: 14 cito SEQUENCE: 14 cito SEQUENCE: 14 cito SEQUENCE: 14			
-11: INNOTE: 21 -21: INNOTE: 21 -21: TPE: DNA -21: CARGANISM: HBG2D -20: SEQ UENCE: 9 gragtgagt cagtgaagt ca -21: LENNET: 26 -21: LENNET: 20 -21: CARGANISM: HBG2D -21: CARGANISM: HBG2D -400 - SEQUENCE: 10 caaaggtgcc cttgagtaa tocagg 26 -10: SEQ UENCE: 10 -21: LENNET: 21 -21: CARGANISM: HBG2D -21: LENNET: 21 -21: CARGANISM: HBG2D -21: CARGANISM: HB	<210> SEO ID NO 9		
<pre><11> UTEF: DNA <11> ORGANISM: HBGZn <11> CAUGASISM: HBGZn <100 SEG ID N0 10 <11> LENGTH: 26 <120 SEG ID N0 10 <11> CAUGASISM: HBGZn <100 SEQUENCE: 10 caaaggtgcc cttggggtca tccagg 26 <10> SEQUENCE: 10 caaaggtgcc cttggggtca tccagg 26 <10> SEQUENCE: 11 ttcccttgggg ggtgccataa a 21 <100 SEQUENCE: 12 ccaaaggtg ctcttctctgg ggt 21 <10> SEQUENCE: 12 ccaaaggtg ctcttctctgg ggt 23 <10> SEQUENCE: 12 ccaaaggtg ctcttctctgg ggt 24 <10> SEQUENCE: 13 ccaaaggtg ctcttctctgg ggt 24 <10> SEQUENCE: 12 ccaaaggtg ctcttctctgg ggt 24 <10> SEQUENCE: 13 <10> SEQUENCE: 12 ccaaaggtg ctcttctctgg ggt 24 <10> SEQUENCE: 13 ccaaaggtg ctcttctctgg ggt 24 <10> SEQUENCE: 12 ccaaaggtg ctcttctctgg ggt 24 <10> SEQUENCE: 13 ccaaaggtg ctcttctctgg ggt 24 <10> SEQUENCE: 13 ccaaaggtg ctcttcttctgg ggt 24 <10> SEQUENCE: 13 ccaaaggtg ccagagtg ggagggg 25 <10 <10> SEQUENCE: 13 ccaaaggtg ctcttcttctgg ggt 24 <10> SEQUENCE: 13 ccaaaggtg ctcttcttctgg ggt 24 <10> SEQUENCE: 13 ccaaaggtg ccagagtg ggagggg 25 <10> SEQUENCE: 13 ccaaaggtg ccagagtg ggagggg 26 <10 <10 <10 <10 <10 <10 <10 <10 <10 <10</pre>	<211> LENGTH: 21		
<pre><11> ORGANISM: HBG2n <400> SEQUENCE: 9 gcaqtqagct caqtqcagtt c 21 </pre> <pre>////////////////////////////////////</pre>	<212> TYPE: DNA		
400. SEQUENCE: 9 gragtagact cagtgeagt c 21 210. SEQUENCE: 10 26 211. SEQUENCE: 10 26 212. TYPE: DNA 21 213. SEQUENCE: 10 26 214. TYPE: DNA 21 215. TYPE: DNA 26 216. SEQUENCE: 11 21 ttccttgggg agtgccetag a 21 216. SEQUENCE: 11 21 ttccttggg agtgccetag a 21 211. LENNET: 21 21 212. TYPE: DNA 21 213. SEQUENCE: 12 21 ccaagcgat ctctctcagg gat 23 210. SEQUENCE: 12 23 ccaagcgat ctctctcagg gat 23 211. LENNET: 27 21 212. TYPE: DNA 23 213. SEQUENCE: 12 23 ccaagcgat ctctctctgg gat 23 214. DENNET: 27 21 215. SEQUENCE: 13 21 cquo sEQUENCE: 13 21 cquo sEQUENCE: 14 21 auxor SEQUENCE: 14 21 auxor SEQUENCE: 14 21	<213> ORGANISM: HBG2n		
gragtgagtt cagtgagtt c 21 <210> SEQ LD N0 10	<400> SEQUENCE: 9		
>			21
>210> SEQ ID N0 10 >211> TERMEN: 26 >212> TERMEN: 26 >200> SEQUENCE: 10 caaaggtgoc cttgagatca toccagg 26 >210> SEQ ID N0 11 >211> TERMEN: 21 >212> TERMEN: 21 >212> TERMEN: 21 >213> ORGANISM: HEG2n <400> SEQUENCE: 11 ttocttggg agtgocataa a 21 >210> SEQ ID N0 12 >211> TERMEN: 23 >212> TERMEN: 23 >212> TERMEN: 23 >212> TERMEN: 23 >213> ORGANISM: S15 <400> SEQUENCE: 12 caaaggtg cctttrgg gat 23 >210> SEQ ID NO 13 >211> TERMEN: 21 >212> TERMEN: 21 >212> TERMEN: 21 >213> ORGANISM: S15 <400> SEQUENCE: 13 organagtg geagaagtag ageagaa 27 >215> TERMEN: 215 <400> SEQUENCE: 14 acgocogcgt agtgtaa 17	geagegaget cagegeaget c		21
-2115 LENGTH : 26 -2125 TURE INN -2125 ORGANISM: HEG2D -4005 SEQUENCE: 10 caaaggtgoc cttgagatca tocagg 26 -2105 SEQ ID N0 11 -2115 LENGTH : 21 -2125 TURE INN -2125 ORGANISM: HEG2D -2135 ORGANISM: HEG2D -4005 SEQUENCE: 11 ttocettggg gatgocataa a 21 -2105 SEQ ID N0 12 -2115 LENGTH : 23 -2125 TURE INN -2125 Comments : 21 -2105 SEQUENCE: 12 comments : 21 -2105 SEQUENCE: 12 comments : 21 -2105 SEQUENCE: 12 comments : 21 -2105 SEQUENCE: 12 -2105 SEQUENCE: 13 cogcaaggtg gcagaagtag agcagaa -21 -2105 SEQUENCE: 14 acgcocgcgt aggtgaa 17	<210> SEO TO NO 10		
<pre>212> TTPE: DNA 213> ORGANISM: HBG2n 400> SEQUENCE: 10 caaaggigcc cttgagatea tccagg 26 210> SEQUENCE: 11 ttccttggg gatgccataa 2 21 210> SEQUENCE: 11 ttccttggg gatgccataa 2 21 210> SEQUENCE: 11 ttccttggg gatgccataa 2 21 210> SEQUENCE: 12 ccaaagcggat ctcttctgg gat 23 210> SEQUENCE: 12 ccaaaggigt ctcttctgg gat 23 210> SEQUENCE: 12 ccaaaggigt ctcttctgg gat 23 210> SEQUENCE: 12 ccaaaggigt ctcttctgg gat 23 210> SEQUENCE: 13 cggcaaggig gcgaagatg agoagaa 27 210> SEQUENCE: 13 cggcaagatg gcgaagatg agoagaa 27 210> SEQUENCE: 14 acgccgcgt aggtgaa 17</pre>	<211> LENGTH: 26		
<pre><13> ORGANISM: HBG2n <400> SEQUENCE: 10 caaaggtgcc cttgagatca tccagg 26 <10> SEQ ID NO 11 <11> LENGTH: 21 <121> IENGTH: 21 <11> Canadagtga gatgccataa a 21 </pre>	<212> TYPE: DNA		
<400> SEQUENCE: 10 26 <210> SEQ ID NO 11 212 <212> TYPE: DNA 213 <400> SEQUENCE: 11 214 ttocttggg gatgocataa a 21 <210> SEQ ID NO 12 212 >211> LENGTH: 23 213 <210> SEQ UENCE: 12 214 orgaaggat otcttotgg gat 23 <210> SEQ UENCE: 12 23 orgaaggat otcttotga gat 23 <210> SEQ UENCE: 13 23 cquos SEQUENCE: 13 23 cquos SEQUENCE: 13 27 <210> SEQ UENCE: 13 213 <210> SEQ UENCE: 13 214 <210> SEQ UENCE: 14 214 <210> SEQ UENCE: 14 214 <210> SEQUENCE: 14 214 <210> SEQUENCE: 14 215 <210> SEQUENCE: 14 214 <210> SEQUENCE: 14 215 <210> SEQUENCE: 14 216 <210> SEQUENCE: 14 217	<213> ORGANISM: HBG2n		
caaaggtgcc cttgggatca tccagg 26 <211> LENGTH: 21	<400> SEQUENCE: 10		
caaaggtgcc cttgagatea tecagg 26 <210> SEQ ID N0 11 <211> DRGANISM: HBG2n <400> SEQUENCE: 11 tteettggga gatgccataa a 21 <210> SEQ ID N0 12 <211> DRGANISM: S15 <400> SEQUENCE: 12 ccaaaggtgct etettetgg gat 23 <210> SEQ ID N0 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 12 ccaaaggtggt egtggagat 23 <210> SEQ ID N0 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 crugecagatg geagaagtag agcagaa 27 <210> SEQ ID N0 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 crugecagatg geagaagtag agcagaa 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgeegegt agtgaa 17			
<pre><10> SEQ ID NO 11 <211> LENNTH: 21 212> TYPE: DNA <213> ORGANISM: HEG2n <400> SEQUENCE: 11 ttccttggg gatgccataa a 21 <210> SEQ ID NO 12 <211> LENNTH: 23 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 12 ccaaagcgat ctcttctgag gat 23 <210> SEQ ID NO 13 <211> LENNTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID NO 14 <211> LENNTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID NO 14 <211> LENNTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 <according of="" td="" ter<="" term="" the="" to=""><td>caaaggtgcc cttgagatca tcc</td><td>cagg</td><td>26</td></according></pre>	caaaggtgcc cttgagatca tcc	cagg	26
<pre>210 - SEQ ID NO 11 212 - TYPE : DNA 213 - ORGANISM: HBG2n 400 - SEQUENCE: 11 ttocttggga gatgocataa a 21 210 - SEQ ID NO 12 211 - LENOTH: 23 212 - TYPE : DNA 213 - ORGANISM: S15 400 - SEQUENCE: 12 coaaagcgat ctcttctgag gat 23 212 - TYPE : DNA 213 - ORGANISM: S15 400 - SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 210 - SEQ ID NO 14 213 - ORGANISM: S15 400 - SEQUENCE: 14 213 - ORGANISM: S15 400 - SEQUENCE: 14 acgcocgcgt aggtgaa 17</pre>			
<pre>-211> LENGTH: 21 -212> TYPE: DNA -213> ORGANISM: HEG2n -400> SEQUENCE: 11 ttoottggga gatgocataa a 21 -210> SEQ ID NO 12 -211> LENGTH: 23 -212> TYPE: DNA -213> ORGANISM: S15 -400> SEQUENCE: 12 ccaaagogat otottotgag gat 23 -210> SEQ ID NO 13 -211> LENGTH: 27 -212> TYPE: DNA -213> ORGANISM: S15 -400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 -210> SEQ ID NO 14 -211> LENGTH: 17 -212> TYPE: DNA -213> ORGANISM: S15 -400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 -210> SEQ ID NO 14 -211> LENGTH: 17 -212> TYPE: DNA -213> ORGANISM: S15 -400> SEQUENCE: 14 -400> SEQUENCE: 14 acgcocgogt aggtgaa 17</pre>	<210> SEQ ID NO 11		
<pre><212> TYPE: DNA <213> ORGANISM: HBG2n <400> SEQUENCE: 11 ttccttggga gatgccataa a 21 <210> SEQ ID NO 12 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 12 ccaaagcgat ctcttctgag gat 23 </pre>	<211> LENGTH: 21		
<pre><113. ORGANISM: HBG2n <400> SEQUENCE: 11 ttoottggga gatgocataa a 21 </pre> <pre><210> SEQ ID No 12 <211> ELNGTH: 23 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 12 ccaaagogat ctottotgag gat 23 </pre> <pre><pre><pre><pre><pre><pre><pre><pre></pre></pre></pre></pre></pre></pre></pre></pre>	<212> TYPE: DNA		
<pre><400> SEQUENCE: 11 ttocttggg gatgocataa a 21 </pre>	<213> ORGANISM: HBG2n		
ttoottggga gatgooataa a 21 <210> SEQ ID NO 12 <211> LENGTH: 23 <213> ORGANISM: S15 <400> SEQUENCE: 12 coaaagogat otottotgag gat 23 <210> SEQ ID NO 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggocaagatg gocagaagtag agcagaa 27 <210> SEQ ID NO 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 agcocgogg aggtgaa	<400> SEQUENCE: 11		
<pre>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>></pre>	tteettqqqa qatqeeataa a		21
<pre><210> SEQ ID N0 12 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 12 ccaaagogat ctcttctgag gat 23 <210> SEQ ID N0 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID N0 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgccgcggt aggtgaa 17</pre>			
<pre>2110 SEQ ID NO 12 2112 TYPE: DNA 2123 ORGANISM: S15 400> SEQUENCE: 12 ccaaagcgat ctcttctgag gat 210> SEQ ID NO 13 2112 LENGTH: 27 2122 TYPE: DNA 2133 ORGANISM: S15 400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 210> SEQ ID NO 14 2112 LENGTH: 17 2122 TYPE: DNA 2133 ORGANISM: S15 2130 ORGANISM: S15 214 215 ORGANISM: S15 2</pre>	010 GEO TE NO 10		
<pre><2115 LENGTH: 23 <2125 TYPE: DNA <2135 ORGANISM: \$15 <400> SEQUENCE: 12 ccaaagcgat ctcttctgag gat 23 </pre> <pre>c210> SEQ ID NO 13 <211> LENGTH: 27 <2125 TYPE: DNA <2135 ORGANISM: \$15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 </pre> <pre>c210> SEQ ID NO 14 <211> LENGTH: 17 <2125 TYPE: DNA <2130 ORGANISM: \$15 <400> SEQUENCE: 14 acgcccgcgt aggtgaa 17</pre>	<210> SEQ 1D NO 12		
<pre>Clip Information (213) ORGANISM: \$15 <400> SEQUENCE: 12 ccaaagcgat ctcttctgag gat 23 </pre>	<211> LENGTH: 25 <212> TVDE• DNA		
<pre><400> SEQUENCE: 12 ccaaagcgat ctcttctgag gat 23 </pre>	<213> ORGANISM: S15		
<pre><400> SEQUENCE: 12 ccaaagcgat ctcttctgag gat 23 </pre>			
ccaaagcgat ctcttctgag gat 23 <210> SEQ ID N0 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID N0 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgccgcggt aggtgaa 17	<400> SEQUENCE: 12		
<pre><210> SEQ ID NO 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 </pre>	ccaaagcgat ctcttctgag gat	t	23
<pre><210> SEQ ID NO 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 </pre>			
<pre><211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 </pre>	<210> SEO TD NO 13		
<pre><212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID NO 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgccgcggt aggtgaa 17</pre>	<211> LENGTH: 27		
<pre><213> ORGANISM: \$15 <400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID NO 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: \$15 <400> SEQUENCE: 14 acgccgcggt aggtgaa 17</pre>	<212> TYPE: DNA		
<400> SEQUENCE: 13 cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID NO 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgccqcggt aggtgaa 17	<213> ORGANISM: S15		
cggcaagatg gcagaagtag agcagaa 27 <210> SEQ ID NO 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgccgcggt aggtgaa 17	<400> SEQUENCE: 13		
<pre>cggcaagatg gcagaagtag agcagaa 27 </pre>			
<pre><210> SEQ ID NO 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgcccgcggt aggtgaa 17</pre>	cggcaagatg gcagaagtag ago	Sagaa	27
<pre><210> SEQ ID NO 14 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgcccgcggt aggtgaa 17</pre>			
<pre><211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgcccgcggt aggtgaa 17</pre>	<210> SEQ ID NO 14		
<pre><212> TIPE: DNA <213> ORGANISM: S15 <400> SEQUENCE: 14 acgcccgcggt aggtgaa 17</pre>	<211> LENGTH: 17		
<400> SEQUENCE: 14 acgcccgcggt aggtgaa 17	<212> TYPE: DNA <213> OBGANTSM: S15		
<400> SEQUENCE: 14 acgccgcggt aggtgaa 17	VII ONGANION: DIJ		
acgccgcggt aggtgaa 17	<400> SEQUENCE: 14		
	acgccgcggt aggtgaa		17

We claim:

60

1. A method for identifying whether a stain contains blood of a newborn human being, comprising the steps of:

- a) obtaining a sample stain comprising blood from a human being; 65
- b) extracting total ribonucleic acid (tRNA) from the sample stain;

c) treating the total RNA with an enzyme;

 d) initiating a reverse-transcription (RT) reaction by treating total RNA with random decamer primers and a reverse transcriptase enzyme to produce cDNA;

e) amplifying the cDNA using HBGv-specific primers consisting of SEQ ID NO: 9 and SEQ ID NO: 7 and

HSK primers with corresponding fluorescently labeled probes;

f) identifying the age of the donor by determining the cycle threshold (Ct) value of a housekeeping gene (HSK) and the Ct value of the HBGv target gene, then 5 subtracting the Ct value of the target gene, from the Ct value of the HSK gene, wherein a positive value would indicate that the blood originates from a newborn human being.

2. The method, as in claim **1**, wherein the reverse transcriptase enzyme is Moloney Murine Leukemia Virus (MMLV-RT).

3. A method, as in claim **1**, wherein 2 variants of hemoglobin (HBG) are used as primers.

4. A method, as in claim **3**, wherein the 2 variants of HBG $_{15}$ are HBG1n and HBG2n.

5. A method, as in claim **4** wherein the primers are segments of HBG1n and HBG2n.

6. A method, as in claim **5** wherein the primers are one or more selected from the group consisting of sequence ID 4, $_{20}$ 5, 6, 7, 8, 9, 10, 11 and 12.

7. A method, as in claim **5** wherein the identifying probes fluoresce and the values are determined by finding the Ct of the HSK and the Ct of each of the variants of HBG and then

subtracting the Ct of the HBGv from the Ct of the HSK, generating a dCt value.

8. A method, as in claim **5**, wherein the HSK is the ribosomal protein, S15.

9. A method, as in claim 5, wherein the age of the newborn is less than 1 week old.

10. A method, as in claim 5, wherein the age of the newborn is less than 5 months old.

11. A method, as in claim **5**, wherein the HSK is glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

12. The method of claim **1**, wherein the total RNA is extracted with a denaturing solution.

13. The method of claim **1**, wherein the extracting procedure is guanidine isothiocyanate-phenol:chloroform.

14. The method of claim 1, wherein the extracted total RNA is precipitated with an organic solvent.

15. The method of claim **1**, wherein the organic solvent is isopropanol.

16. The method of claim **1**, wherein the enzyme used to treat the extracted total RNA is deoxyribonuclease I (DNase I).

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.: 7,276,340 B1APPLICATION NO.: 11/232313DATED: October 2, 2007INVENTOR(S): John Ballantyne

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 1 lines 3-4 insert:

--STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This subject invention was made with government support by Technical Support Working Group on Counter Terrorism (TSWG), federal contract number TSWG Task IS-FO-159. The government has certain rights in this invention.--

Signed and Sealed this Fifteenth Day of March, 2011

David J. Kappos Director of the United States Patent and Trademark Office